ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Educational Symposium

Autosomal Dominant Polycystic Kidney Disease: Risk Assessment and Management

October 22, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

ADPKD, the most common monogenic cause of kidney failure in humans, primarily caused by mutations of PKD1 or PKD2, which encode the proteins polycystin 1 and polycystin 2, respectively. Progression of ADPKD can be highly variable. Age, eGFR, and total kidney volume are factors used to predict the risk of disease progression.

Measures that slow the progression of ADPKD include controlling blood pressure, particularly with the use of ACE inhibitors or ARBs, maintaining sufficient hydration, and treating urinary tract infections and, for patients whose kidney disease is rapidly progressing, taking tolvaptan.

This symposium provides updates about assessing symptoms and risk in patients with ADPKD and reviews the management of renal and nonrenal complications.

Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

  • Describe the risk of progression in individuals with ADPKD
  • Discuss current best practices in the pharmacological and non-pharmacological management of ADPKD

Learning Pathway(s)

  • Genetic Diseases of the Kidneys

Moderator

  • Fouad T. Chebib, MD, FASN

Presentations

  • Introduction
    01:00 PM - 01:10 PM
    Fouad T. Chebib, MD, FASN 
  • Assessing Symptoms and Risks in ADPKD
    01:10 PM - 01:35 PM
    Ron T. Gansevoort, MD, PhD, FASN 
  • Current Best Practices in the Management of ADPKD
    01:35 PM - 02:00 PM
    Ronald D. Perrone, MD, FASN